Рабиа Асле

Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models

Human Gut Microbiota in Cardiovascular Disease

Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

Impact of age over 70 years in the new allocation system on the outcomes of heart transplantation in the US

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Endomyocardial biopsy in clinical practice: the diagnostic yield and insights from a 5-year single-center experience

Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: Insight from the United Network for Organ Sharing

Cardiac magnetic resonance imaging in heart transplant recipients with biopsy-negative graft dysfunction

Ser194Leu DSG2 mutation, associated with arrhythmogenic left ventricular cardiomyopathy and ventricular tachycardia

Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight

Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support

Diurnal cardio-respiratory changes in ambulatory individuals deciphered using a multi-parameter wearable device

Real-Life Utilization of Criteria Guidelines for Diagnosis of Cardiac Sarcoidosis (CS)

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Management of Acute Myocarditis and Post-hospitalization Follow-up: A Position Statement from the Israel Heart Society

Definition and Diagnosis of Acute Myocarditis: A Position Statement of the Israel Heart Society

Cardiac Transplantation: Physiology and Natural History of the Transplanted Heart

PET Assessment of Cardiac Allograft Vasculopathy After Heart Transplantation: Beyond Coronary Angiography and IVUS

Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice

A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial

Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients

Giant Intracardiac Lipoma: A Case Report and the Role of Multimodality Cardiac Imaging

A case series of eosinophilic myocarditis: different faces of the same coin

A Rare Case of Endocarditis and Mycotic Pseudoaneurysm of the Left Ventricle Caused by Escherichia coli Following Transcatheter Aortic Valve Replacement

Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database

Evolution of In-Hospital Outcomes Among Left Ventricular Assist Device Recipients

Characteristics and outcomes of left ventricular assist device recipients transplanted before and after the new donor heart allocation system

Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation

Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly

Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study

Outcomes after heart transplantation in patients with cardiac sarcoidosis

Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis

In Search of Clinical Impact: Advanced Monitoring Technologies in Daily Heart Failure Care

Persistent sex differences in outcomes after coronary heart disease: time to move from observation to action

Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation

Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm

Predictors of Hypoxemia and Related Adverse Outcomes in Patients Hospitalized with COVID-19: A Double-Center Retrospective Study

The Reply

Analysis of Trends and Outcomes of 90 and 180 Day Readmissions After Left Ventricular Assist Device Implantation

State-of-the-art machine learning improves predictive accuracy of 1-year survival after heart transplantation

Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation

Longitudinal trends and outcomes of adult heart transplantation in the U.S

Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?

Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?

Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation

Trends and outcomes of device-related 30-day readmissions after left ventricular assist device implantation

Sex Differences in Outcomes After Myocardial Infarction in the Community

Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients

Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens

Coronary Disease Surveillance in the Community: Angiography and Revascularization

Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices

Left ventricular assist devices as destination therapy in stage D heart failure

The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices

Utilization of Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock Complicating Acute Myocardial Infarction and High-Risk Percutaneous Coronary Interventions

Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation

Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation

Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation

Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options

Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Trends in In-Hospital Mortality, Length of Stay, Nonroutine Discharge, and Cost Among End-Stage Renal Disease Patients on Dialysis Hospitalized With Heart Failure (2001-2014)

Trends in utilization, mortality, major complications, and cost after total artificial heart implantation in the United States (2009-2015)

Haptoglobin Phenotype Is Associated With High-Density Lipoprotein-Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease

Cardiovascular risk prediction in older adults with the use of biomarkers

The Iron-Klotho-VDR Axis Is a Major Determinant of Proximal Convoluted Tubule Injury in Haptoglobin 2-2 Genotype Diabetic Nephropathy Patients and Mice

Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients

Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients

Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients

Danazol treatment of gastrointestinal bleeding in left ventricular assist device-supported patients

Reply: Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?

Hemodynamic Assessment of Patients With and Without Heart Failure Symptoms Supported by a Continuous-Flow Left Ventricular Assist Device

Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation

Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation

Regional Variation in Mortality, Major Complications, and Cost After Left Ventricular Assist Device Implantation in the United States (2009 to 2014)

Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis

Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients

Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease

The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus

Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience

Anti-oxidative treatment with vitamin E improves peripheral vascular function in patients with diabetes mellitus and Haptoglobin 2-2 genotype: A double-blinded cross-over study

Regional Variation in Mortality, Length of Stay, Cost, and Discharge Disposition Among Patients Admitted for Heart Failure in the United States

Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes

Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial

Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability

Haptoglobin genotype-dependent differences in macrophage lysosomal oxidative injury

Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy?

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus

Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype

Cholesterol efflux capacity and atherosclerosis

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype

Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype

Haptoglobin: basic and clinical aspects

Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus

Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype

Hypothesis--haptoglobin genotype and diabetic nephropathy

Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability

In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease

Haptoglobin genotype determines myocardial infarct size in diabetic mice

Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo

Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction

Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo

Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes

Tyrosine kinases inhibitors block Fas-mediated deleterious effects in normoxic and hypoxic ventricular myocytes

Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease

Рабиа Асле

Образование

Научные публикации